Surgery Partners has seen its share price fall sharply over the past few years, yet the stock currently screens as cheap on broad valuation checks. That contrast between prolonged share price weakness and an apparently attractive valuation setup is what investors now need to weigh. Over the past 5 years, Surgery Partners stock has declined 70.8%, which means long term holders have absorbed a heavy drawdown that may now be influencing sentiment around the valuation. Recent growth in higher...

Idaho Falls sale signals shift to pure-play surgical focus.

Surgery Partners’ second quarter results were received positively by the market, with management highlighting that revenue and adjusted EBITDA came in ahead of expectations. CEO Eric Evans credited growth in higher-acuity surgical procedures—particularly in orthopedics, vascular, and spine—as a primary driver, despite overall surgical case volumes remaining flat. Management also pointed to the company’s ongoing focus on recruiting new physicians and maintaining strong relationships with clinical

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the outpatient & specialty care stocks, including Surgery Partners (NASDAQ:SGRY) and its peers.

Healthcare company Surgery Partners (NASDAQ:SGRY) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 2.7% year on year to $848.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP profit of $0.10 per share was 59.6% above analysts’ consensus estimates.

Healthcare company Surgery Partners (NASDAQ:SGRY) will be announcing earnings results this Monday before market hours. Here’s what to expect.

Surgery Partners (NASDAQ:SGRY) reported second-quarter 2026 revenue and adjusted EBITDA above its internal expectations, while reaffirming its full-year outlook ahead of the anticipated sale of its Idaho Falls market operations to Intermountain Health. The company reported net revenue of approximat

Surgery Partners, Inc. (NASDAQ:SGRY) shares slipped 0.

Surgery Partners (SGRY) delivered earnings and revenue surprises of +400.00% and +1.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare company Surgery Partners (NASDAQ:SGRY) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 2.7% year on year to $848.9 million. The company expects the full year’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP profit of $0.10 per share was 49.4% above analysts’ consensus estimates.

CryoPort (CYRX) delivered earnings and revenue surprises of 0.00% and +1.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biodesix (BDSX) delivered earnings and revenue surprises of +17.44% and +2.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change with its stock at $85.44 and a value score of 5, which can help...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Surgery Partners (SGRY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.